Ifbm's to promote the specific attachment of target analytes to the surface of orthopedic implants

Abstract

The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material (“implant module”) and at least one binding module that selectively binds to a target analyte or that is designed to have a desired effect (“analyte module”). The modules are connected by a linker. In some embodiments, the IFBM coating acts to promote the recognition and attachment of target analytes to surface of the device. The IFBM coating improves the performance of implanted medical devices, for example, by promoting osteointegration of the implant.

1 - 19 . (canceled) 
     
     
         20 . An implant comprising a polypeptide that binds to a bone morphogenetic protein, wherein the polypeptide is selected from the group consisting of:
 (i) the polypeptide set forth in any one of SEQ ID NOs: 27 or 73;   (ii) the polypeptide set forth in any one of SEQ ID NOs: 11-24, 44-72, or 74;   (iii) the polypeptide having at least 70% identity to any one of the polypeptides set forth in SEQ ID NOs: 11-24, 44-55, 57-72, or 74;   (iv) the polypeptide having at least 75% identity to any one of the polypeptides set forth in SEQ ID NOs: 11-24, 44-72, or 74; and   (v) the polypeptide that is a conservatively substituted variant of any one of the polypeptides set forth in SEQ ID NOs: 11-24, 44-72, or 74.   
     
     
         21 . The implant of  claim 20 , wherein the polypeptide is set forth in any one of SEQ ID NOs: 27 or 73 and the polypeptide consists of no more than 40 amino acids in length. 
     
     
         22 . The implant of  claim 20 , wherein the polypeptide is set forth in any one of SEQ ID NOs: 27 or 73 and the polypeptide consists of no more than 30 amino acids in length. 
     
     
         23 . The implant of  claim 20 , wherein the polypeptide is set forth in any one of SEQ ID NOs: 27 or 73 and the polypeptide consists of no more than 20 amino acids in length. 
     
     
         24 . The implant of  claim 20 , wherein the polypeptide is set forth in any one of SEQ ID NOs: 27 or 73 and the polypeptide consists of no more than 17 amino acids in length. 
     
     
         25 . The implant of  claim 20 , wherein the polypeptide is set forth in any one of SEQ ID NOs: 27 or 73 and the polypeptide consists of no more than 10 amino acids in length. 
     
     
         26 . The implant of  claim 20 , wherein the polypeptide is set forth in any one of SEQ ID NOs: 27 or 73 and the polypeptide consists of no more than 7 amino acids in length. 
     
     
         27 . The implant of  claim 20 , wherein the bone morphogenetic protein is bone morphogenetic protein-2. 
     
     
         28 . A method for promoting bone formation, the method comprising placing a polypeptide that binds to a bone morphogenetic protein (BMP) at a site for bone formation, wherein the polypeptide binds and presents the BMP to promote the bone formation, and wherein the polypeptide is selected from the group consisting of:
 (i) the polypeptide set forth in any one of SEQ ID NOs: 27 or 73;   (ii) the polypeptide set forth in any one of SEQ ID NOs: 11-24, 44-72, or 74;   (iii) the polypeptide having at least 70% identity to any one of the polypeptides set forth in SEQ ID NOs: 11-24, 44-55, 57-72, or 74;   (iv) the polypeptide having at least 75% identity to any one of the polypeptides set forth in SEQ ID NOs: 11-24, 44-72, or 74; and   (v) the polypeptide that is a conservatively substituted variant of any one of the polypeptides set forth in SEQ ID NOs: 11-24, 44-72, or 74.   
     
     
         29 . The method of  claim 28 , wherein the bone morphogenetic protein is bone morphogenetic protein-2. 
     
     
         30 . A method for promoting osteointegration, and/or accelerating healing, and/or reducing inflammation at a site of an implant, the method comprising localizing a polypeptide that binds to a bone morphogenetic protein (BMP) at the site of the implant, wherein the polypeptide binds and presents the BMP for the promoted osteointegration, and/or accelerated healing, and/or reduced inflammation, and wherein the polypeptide is selected from the group consisting of:
 (i) the polypeptide set forth in any one of SEQ ID NOs: 27 or 73;   (ii) the polypeptide set forth in any one of SEQ ID NOs: 11-24, 44-72, or 74;   (iii) the polypeptide having at least 70% identity to any one of the polypeptides set forth in SEQ ID NOs: 11-24, 44-55, 57-72, or 74;   (iv) the polypeptide having at least 75% identity to any one of the polypeptides set forth in SEQ ID NOs: 11-24, 44-72, or 74; and   (v) the polypeptide that is a conservatively substituted variant of any one of the polypeptides set forth in SEQ ID NOs: 11-24, 44-72, or 74.   
     
     
         31 . The method of  claim 30 , wherein the bone morphogenetic protein is bone morphogenetic protein-2. 
     
     
         32 . A method for binding bone morphogenetic protein (BMP) in vitro, the method comprising incubating a BMP with a polypeptide that binds to the BMP under conditions suitable for binding, wherein the polypeptide is selected from the group consisting of:
 (i) the polypeptide set forth in any one of SEQ ID NOs: 27 or 73;   (ii) the polypeptide set forth in any one of SEQ ID NOs: 11-24, 44-72, or 74;   (iii) the polypeptide having at least 70% identity to any one of the polypeptides set forth in SEQ ID NOs: 11-24, 44-55, 57-72, or 74;   (iv) the polypeptide having at least 75% identity to any one of the polypeptides set forth in SEQ ID NOs: 11-24, 44-72, or 74; and   (v) the polypeptide that is a conservatively substituted variant of any one of the polypeptides set forth in SEQ ID NOs: 11-24, 44-72, or 74.   
     
     
         33 . The method of  claim 32 , wherein the bone morphogenetic protein is bone morphogenetic protein-2.